Acrivon Therapeutics Inc

ACRV

Company Profile

  • Business description

    Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

  • Contact

    480 Arsenal Way
    Suite 100
    WatertownMA02472
    USA

    T: +1 617 207-8979

    https://www.acrivon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    78

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.702.300.03%
CAC 407,715.607.87-0.10%
DAX 4024,084.8611.190.05%
Dow JONES (US)44,406.36422.17-0.94%
FTSE 1008,811.615.080.06%
HKSE24,134.74246.911.03%
NASDAQ20,412.52188.59-0.92%
Nikkei 22539,688.81101.130.26%
NZX 50 Index12,859.0294.070.74%
S&P 5006,229.9849.37-0.79%
S&P/ASX 2008,590.701.400.02%
SSE Composite Index3,497.4824.350.70%

Market Movers